BIIB FY2025 SEC EDGAR DEF 14A #39 of 168 in industry

Biogen Inc. CEO pay ratio

The CEO earned $23.6M in FY2025 against median worker pay of $209,257 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-28
Industry
Chemicals & Pharmaceuticals
Industry rank
#39/168

Data updated August 2026

Subscribe to Biogen Inc. CEO pay filing updates (RSS)

CEO-to-worker pay ratio
113:1
Moderate (Scale: 0–1000:1)
CEO pay
$23.6M
Median worker
$209,257

Answer first

Biogen Inc.'s FY2025 CEO total of $23.6M ranks #120 of 1,423 complete filings; its 113:1 pay ratio ranks #582. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $209,257. Industry placement uses the FY2025 SIC-28 peer cohort (# 39 of 168, 77th percentile - top quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#120
$23.6M of 1,423 FY2025
Ratio rank
#582
113:1 of 1,423
Industry pct
77th
top quartile of industry peers by pay ratio

How Biogen Inc. ranks nationally

Biogen Inc. CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$23,646,004 Top 8% higher than 92% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). Below this entry. $15,000,000–$17,500,000: 88 companies (6%). Below this entry. $17,500,000–$20,000,000: 54 companies (4%). Below this entry. $20,000,000–$22,500,000: 24 companies (2%). Below this entry. $22,500,000–$25,000,000: 34 companies (2%). This entry sits in this band. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Biogen Inc. vs. Chemicals & Pharmaceuticals peers

CEO total pay ($23.6M) against pay ratio (113:1) for Biogen Inc. (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both3092907.18475861.013858815.019241768.924624722.938.4:158.2:178:197.8:1117.6:1CEO total payPay ratio (CEO : median worker)Biogen Inc., CEO total pay: 23646004 · Pay ratio (CEO : median worker): 113:1Biogen Inc.Ani Pharmaceuticals Inc, CEO total pay: 10254756 · Pay ratio (CEO : median worker): 114:1Ani Pharmaceuticals IncCronos Group Inc., CEO total pay: 4071626 · Pay ratio (CEO : median worker): 112:1Cronos Group Inc.Perimeter Solutions, Inc., CEO total pay: 8062080 · Pay ratio (CEO : median worker): 114:1Perimeter Solutions, Inc.Biomarin Pharmaceutical Inc, CEO total pay: 21927563 · Pay ratio (CEO : median worker): 109:1Biomarin Pharmaceutical Inc
Biogen Inc. vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Biogen Inc.'s structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Biogen Inc.

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
113:1
FY2025
vs prior FY
-19:1
from FY2024 132:1
CEO $ YoY
-2.2%
$23.6M latest
Filings shown
5
FY2021–2025
Biogen Inc. CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $17.7M - $163,551 108:1 -
2022 $3.5M -80% $19,403 182:1 +74:1
2023 $4.1M +15% $176,953 23:1 -159:1
2024 $24.2M +494% $183,081 132:1 +109:1
2025 $23.6M -2.2% $209,257 113:1 -19:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 875045, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
113:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$23.6M
Companies in Industry
168
vs. Industry Median
Above
#39 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Biogen Inc.: MID · PEAK pay ratio

Biogen Inc.'s FY2025 ratio 113:1 ranks #39 of 168 Chemicals & Pharmaceuticals filers (77th percentile). the CEO earned 113× the median employee ($209,257) in FY2025.

Median employee $209,257 (ELITE-MED); MID · PEAK stamps put about 113 median-wage years per CEO year.

CEO Total Pay

$23.6M

FY2025 Summary Compensation, well above median

Pay Ratio

113:1

Near industry median

Biogen Inc. in the higher Chemicals & Pharmaceuticals third

Biogen Inc.'s FY2025 ratio 113:1 ranks #39 of 168 Chemicals & Pharmaceuticals filers (77th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Biogen Inc.'s $23.6M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #120 and ratio rank #582 split - treat 113:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$23.6M
Median Employee Pay
$209,257
Pay Ratio
113:1
Filing Date
2026-04-28

Company Info

Ticker
BIIB
CIK
875045
Industry
Chemicals & Pharmaceuticals
SIC Code
2836
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 875045, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Biogen Inc.'s FY2025 ratio 113:1 ranks #39 of 168 Chemicals & Pharmaceuticals filers (77th percentile).

Read with Biogen Inc.

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MID · PEAK · ELITE-MED.

Harrow, Inc. · PEAK

ABS(ceo_total_comp) peer at $23.6M (Δ $40K lighter vs Biogen Inc.); STEEP · HIGH-MED vs this page's MID · PEAK · ELITE-MED.
PROCEPT BioRobotics Corp · PEAK

ABS(ceo_total_comp) peer at $23.6M (Δ $96K lighter vs Biogen Inc.); MID · ELITE-MED vs this page's MID · PEAK · ELITE-MED.
Boston Scientific Corp · PEAK

ABS(ceo_total_comp) peer at $23.5M (Δ $114K lighter vs Biogen Inc.); HIGH · PAR-MED vs this page's MID · PEAK · ELITE-MED.
Hewlett Packard Enterprise Co · PEAK

ABS(ceo_total_comp) peer at $23.5M (Δ $163K lighter vs Biogen Inc.); HIGH · HIGH-MED vs this page's MID · PEAK · ELITE-MED.
Ani Pharmaceuticals Inc (SIC 28 pole)

Ani Pharmaceuticals Inc stamps MID · HEAVY nearest in-SIC by ABS(pay_ratio) to Biogen Inc.'s MID filing.
National dual ranks · #120/#582

Biogen Inc.'s FY2025 package sits #120 by CEO dollars and #582 by ratio under PEAK · MID.
Comp structure · PEAK

Biogen Inc.'s PEAK CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for Biogen Inc. (CIK 875045), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.